Clinuvel receives approval to begin Phase II trials in Solar Urticaria
•
Fourth indication enters clinical trials
•
Objective of photo protection in multicenter trial
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) announces that ethics approval has been granted to commence a Phase II clinical trial of its photo protective drug, CUV1647, in Solar Urticaria (SU).
SU is one of the five UV and light-related indications identified by Clinuvel to test its photo protective drug, CUV1647, and will be the fourth indication to commence clinical trials. For all the photodermatoses treated by CUV1647, the common factor is melanin compromised skin. The treatment of CUV1647 is preventative rather than therapeutic.
announcement out
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.37 |
Change
0.130(0.85%) |
Mkt cap ! $770.0M | |||
| Open | High | Low | Value | Volume |
| $15.36 | $15.54 | $15.18 | $1.274M | 82.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237 | $15.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 282 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |